首页> 外文期刊>Bone marrow transplantation >Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged >= 60
【24h】

Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged >= 60

机译:年龄对同种异体造血细胞移植后预后的影响:单项中心研究,年龄> = 60

获取原文
获取原文并翻译 | 示例
           

摘要

Reduced intensity conditioning regimens lead to an increasing use of allogeneic hematopoietic cell transplantation (HCT) in elderly patients. We retrospectively analyzed 151 patients aged >= 60 receiving allogeneic HCT 2000-2012 at our center. Median age was 66 years. Kaplan-Meier estimated 3-year OS was 42% with a median follow-up of 38 months. Cumulative incidences of progression and non-relapse mortality after 3 years were 38 and 24%. OS was better in the group of patients >65 years with a Kaplan-Meier estimated OS of 50% vs 34%, P = 0.060. We observed a significant influence of donor age (<50 years: 53% vs >50 years: 30%, P = 0.017) and gender match (matched: 57% vs mismatched: 32%, P = 0.007) on outcome. The use of a matched related donor was inferior compared with a matched or mismatched unrelated donor (19% vs 47%, P = 0.015). On multivariate analysis there was an increased hazard ratio for a non-gender-matched HLA-matched-related donor (hazard ratio 3.23, 95% confidence interval 1.55-6.74, P = 0.002). Age had no significant impact on OS (P = 0.414). In conclusion, the data suggest that older age alone has no negative impact on the outcome of allogeneic HCT. Transplant decision should be tailored to disease risk and patient performance status rather than age.
机译:强度调节方案的减少导致老年患者同种异体造血细胞移植(HCT)的使用增加。我们在我们中心回顾性分析了151名年龄≥60岁的接受异基因HCT 2000-2012的患者。中位年龄为66岁。 Kaplan-Meier估计3年OS为42%,中位随访时间为38个月。 3年后累积的进展和非复发死亡率发生率分别为38%和24%。 Kaplan-Meier估计的OS分别为50%和34%,> 65岁的患者中OS更好,P = 0.060。我们观察到供者年龄(<50岁:53%vs> 50岁:30%,P = 0.017)和性别匹配(匹配:57%vs不匹配:32%,P = 0.007)有显着影响。与相配或不相配的不相干供体相比,匹配相近的供体的使用较差(19%vs 47%,P = 0.015)。在多变量分析中,非性别匹配的HLA匹配相关供体的危险比增加(危险比3.23,95%置信区间1.55-6.74,P = 0.002)。年龄对OS没有显着影响(P = 0.414)。总之,数据表明,仅年龄对异基因HCT的结果没有负面影响。移植决策应根据疾病风险和患者表现状况(而非年龄)而定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号